Immune Therapeutics, Inc. – OTC:IMUN

Immune Therapeutics stock price today

$0.7
+0.60
+652.69%
Financial Health
0
1
2
3
4
5
6
7
8
9

Immune Therapeutics stock price monthly change

+30.99%
month

Immune Therapeutics stock price quarterly change

-62.37%
quarter

Immune Therapeutics stock price yearly change

-93.16%
year

Immune Therapeutics key metrics

Market Cap
 39.10M
Enterprise value
 36.53M
P/E
 -1.02
EV/Sales
 N/A
EV/EBITDA
 -11.04
Price/Sales
 N/A
Price/Book
 -13.85
PEG ratio
 N/A
EPS
 -0.02
Revenue
 N/A
EBITDA
 -900.22K
Income
 -1.59M
Revenue Q/Q
 N/A
Revenue Y/Y
 N/A
Profit margin
 0%
Oper. margin
 0%
Gross margin
 0%
EBIT margin
 0%
EBITDA margin
 N/A

Get more financial ratios!

  • Every financial ratio you might need

  • 10 years history

  • Forward ratios (Analysts estimates)

Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Immune Therapeutics stock price history

Immune Therapeutics stock forecast

Immune Therapeutics financial statements

Profit Margin

Immune Therapeutics, Inc. (OTC:IMUN): Profit margin
Dec 2022 0 -275.65K
Mar 2023 0 -430.41K
Jun 2023 0 -504.23K
Sep 2023 0 -388.76K
IMUN income statement history

Debt to Assets

Immune Therapeutics, Inc. (OTC:IMUN): Debt to assets
Dec 2022 963719 3.47M 360.81%
Mar 2023 796728 3.57M 448.87%
Jun 2023 758672 3.86M 508.92%
Sep 2023 732000 4.21M 575.39%
IMUN balance sheet history

Cash Flow

Immune Therapeutics, Inc. (OTC:IMUN): Cash Flow
Dec 2022 415.04K -500M 50K
Mar 2023 -265.49K 0 150K
Jun 2023 -314.02K 0 296.45K
Sep 2023 11.05K 0 -23.95K
IMUN cash flow history

Immune Therapeutics other data

Immune Therapeutics
Insider Trading

Immune Therapeutics, Inc. (OTC:IMUN): Insider trades (number of shares)
Period Buy Sel
Feb 2023 409000 0
Transaction Date Insider Security Shares Price per share Total value Source
Purchase
FARMER GLEN A officer: Chief Financial Officer
 Common Stock 409,000 $0.05 $18,405
Purchase
GOSTANIAN RICHARD other: large share & note holder
 common 30,000 $0.02 $600
Purchase
GOSTANIAN RICHARD other: large share & note holder
 common 10,000 $0.02 $230
Purchase
DAILEY ROBERT JACKMAN other: Significant Investor
 Common stock 20,000 N/A N/A
Purchase
DAILEY ROBERT JACKMAN other: Significant Investor
 Common stock 5,000 N/A N/A
Purchase
DAILEY ROBERT JACKMAN other: Significant Investor
 Common stock 5,000 N/A N/A
Purchase
GOSTANIAN RICHARD other: large share & note holder
 common 50,000 $0.01 $600
Purchase
GOSTANIAN RICHARD other: large share & note holder
 common 15,000 $0.01 $210
Purchase
GOSTANIAN RICHARD other: large share & note holder
 common 1,250 $0.02 $20
Purchase
GOSTANIAN RICHARD other: large share & note holder
 common 10,000 $0.02 $230
IMUN insider trading transactions

Immune Therapeutics
Executives

Insider Compensation
Mr. Kevin J. Phelps CPA (1955) Pres, Chief Executive Officer, Chief Financial Officer & Director
 $298,080
Mr. Peter Aronstam Ph.D. (1953) Sec. $59,800

Frequently Asked Questions (FAQ)

  • What's the price of Immune Therapeutics stock today?

    One share of Immune Therapeutics stock can currently be purchased for approximately $0.7.

  • When is Immune Therapeutics's next earnings date?

    Unfortunately, Immune Therapeutics's (IMUN) next earnings date is currently unknown.

  • Does Immune Therapeutics pay dividends?

    No, Immune Therapeutics does not pay dividends.

  • How much money does Immune Therapeutics make?

    Immune Therapeutics has a market capitalization of 39.10M.

  • What is Immune Therapeutics's stock symbol?

    Immune Therapeutics, Inc. is traded on the OTC under the ticker symbol "IMUN".

  • What is Immune Therapeutics's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Immune Therapeutics?

    Shares of Immune Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Immune Therapeutics's key executives?

    Immune Therapeutics's management team includes the following people:

    • Mr. Kevin J. Phelps CPA Pres, Chief Executive Officer, Chief Financial Officer & Director(age: 70, pay: $298,080)
    • Mr. Peter Aronstam Ph.D. Sec.(age: 72, pay: $59,800)

  • When Immune Therapeutics went public?

    Immune Therapeutics, Inc. is publicly traded company for more then 15 years since IPO on 20 Aug 2010.

  • What is Immune Therapeutics's official website?

    The official website for Immune Therapeutics is immunetherapeutics.com.

  • Where are Immune Therapeutics's headquarters?

    Immune Therapeutics is headquartered at 2431 Aloma Avenue, Winter Park, FL.

  • How can i contact Immune Therapeutics?

    Immune Therapeutics's mailing address is 2431 Aloma Avenue, Winter Park, FL and company can be reached via phone at +888 6138802.

Immune Therapeutics company profile:

Immune Therapeutics, Inc.

immunetherapeutics.com
Exchange:

OTC

Full time employees:

0

Industry:

Biotechnology

Sector:

Healthcare

Immune Therapeutics, Inc. does not have significant operations. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in October 2014. Immune Therapeutics, Inc. is headquartered in Orlando, Florida.

+888 6138802
2431 Aloma Avenue
Winter Park, FL 32792

CIK: 0001559356
ISIN: US45252A3059
CUSIP: 45252A305